FDA unveils top 5 priorities for reworking its Covid-19 response moving forward
Following the lightning-quick FDA reviews of the first three Covid-19 vaccines, and the agency’s bowing to political pressure on some of its emergency authorizations (i.e. with hydroxychloroquine and convalescent plasma), the FDA last Friday unveiled the top 5 Covid-related work areas it will prioritize moving forward.
First and foremost, the FDA said it will review its processes for issuing emergency use authorizations (EUAs) and identify areas for improvement. Stephen Hahn, the FDA’s former commissioner, admitted to moving more quickly on some of the EUAs because of political pressure, and he had to apologize for overstating the efficacy of convalescent plasma at a press conference after the agency issued an EUA for the treatment last August.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.